Cargando…
Targeting CD83 for the treatment of graft-versus-host disease
Graft-versus-host disease (GVHD) is a common and often fatal complication of bone marrow transplantation. Antigen-presenting cells from donor and recipient play a critical role in the initiation and maintenance of GVHD. CD83, which is expressed in activated lymphocytes and dendritic cells, is regard...
Autores principales: | WANG, XIONGFEI, WEI, MING Q., LIU, XIAOSONG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702702/ https://www.ncbi.nlm.nih.gov/pubmed/23837028 http://dx.doi.org/10.3892/etm.2013.1033 |
Ejemplares similares
-
Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease
por: Wilson, John, et al.
Publicado: (2009) -
Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease
por: Wilson, John, et al.
Publicado: (2009) -
Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia
por: Kim, Sena, et al.
Publicado: (2020) -
Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
por: Li, Ziduo, et al.
Publicado: (2020) -
Advances in the treatment of acute graft-versus-host disease
por: Qian, Liren, et al.
Publicado: (2013)